The Journal of Pediatrics
Volume 152, Issue 5 , Pages 622-628 , May 2008

Dermatological Complications of Continuous Subcutaneous Insulin Infusion in Children and Adolescents

  • Louise S. Conwell, MBBS(Hons), PhD, FRACP

      Affiliations

    • Division of Endocrinology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Elena Pope, MD, FRCPC

      Affiliations

    • Division of Pediatric Medicine, Section of Dermatology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Ana M. Artiles, RN, CDE

      Affiliations

    • Endocrine Program, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Arun Mohanta, RDMS

      Affiliations

    • Department of Diagnostic Imaging, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Alan Daneman, MB, BCh, FRACR, FRCPC

      Affiliations

    • Department of Diagnostic Imaging, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Denis Daneman, MB, BCh, FRCPC

      Affiliations

    • Division of Endocrinology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
    • Corresponding Author InformationReprint requests: Denis Daneman, MB, BCh, FRCPC, Division of Endocrinology, Department of Pediatrics, Hospital for Sick Children, 555 University Ave, Toronto, Ontario, Canada M5G 1X8.

Received 25 April 2007 ,Revised 30 July 2007 ,Accepted 4 October 2007.

References 

  1. Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care. 2006;29:340–344
  2. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159–2167
  3. White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr. 2001;139:804–812
  4. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus (The Diabetes Control and Complications Trial Research Group). N Engl J Med. 1993;329:977–986
  5. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr. 1994;125:177–188
  6. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653
  7. Fox LA, Buckloh LM, Smith SD, Wysocki T, Mauras N. A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes. Diabetes Care. 2005;28:1277–1281
  8. Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE. A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care. 2005;28:15–19
  9. Wintergerst KA, Hargadon S, Hsiang HY. Continuous subcutaneous insulin infusion in neonatal diabetes mellitus. Pediatr Diabetes. 2004;5:202–206
  10. Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol. 2003;4:661–667
  11. Ampudia-Blasco FJ, Hasbum B, Carmena R. A new case of lipoatrophy with lispro insulin in insulin pump therapy: is there any insulin preparation free of complications?. Diabetes Care. 2003;26:953–954
  12. Griffin ME, Feder A, Tamborlane WV. Lipoatrophy associated with lispro insulin in insulin pump therapy: an old complication, a new cause?. Diabetes Care. 2001;24:174
  13. van Faassen I, Razenberg PP, Simoons-Smit AM, van der Veen EA. Carriage of Staphylococcus aureus and inflamed infusion sites with insulin-pump therapy. Diabetes Care. 1989;12:153–155
  14. Mecklenburg RS, Benson EA, Benson JW, Fredlund PN, Guinn T, Metz RJ, et al. Acute complications associated with insulin infusion pump therapy (Report of experience with 161 patients). JAMA. 1984;252:3265–3269
  15. Guinn TS, Bailey GJ, Mecklenburg RS. Factors related to discontinuation of continuous subcutaneous insulin-infusion therapy. Diabetes Care. 1988;11:46–51
  16. Chantelau E, Lange G, Sonnenberg GE, Berger M. Acute cutaneous complications and catheter needle colonization during insulin-pump treatment. Diabetes Care. 1987;10:478–482
  17. Chantelau E, Spraul M, Muhlhauser I, Gause R, Berger M. Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologia. 1989;32:421–426
  18. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, et al. CDC growth charts: United States. Adv Data. 2000;1–27
  19. Teutsch SM, Herman WH, Dwyer DM, Lane JM. Mortality among diabetic patients using continuous subcutaneous insulin-infusion pumps. N Engl J Med. 1984;310:361–368
  20. Toxic-shock syndrome in a patient using a continuous subcutaneous insulin infusion pump—Idaho. MMWR Morb Mortal Wkly Rep. 1983;32:404–406412
  21. Garcia Hidalgo L. Dermatological complications of obesity. Am J Clin Dermatol. 2002;3:497–506
  22. Scheinfeld NS. Obesity and dermatology. Clin Dermatol. 2004;22:303–309
  23. Hahler B. An overview of dermatological conditions commonly associated with the obese patient. Ostomy Wound Manage. 2006;52:34–3638, 40
  24. Chantelau E, Reuter M, Schotes S, Starke AA. Severe lipoatrophy with human insulin: successfully treated by CSII. Diabet Med. 1993;10:580–581
  25. Nagai T, Nagai Y, Tomizawa T, Mori M. Immediate-type human insulin allergy successfully treated by continuous subcutaneous insulin infusion. Intern Med. 1997;36:575–578
  26. Naf S, Esmatjes E, Recasens M, Valero A, Halperin I, Levy I, et al. Continuous subcutaneous insulin infusion to resolve an allergy to human insulin. Diabetes Care. 2002;25:634–635
  27. Schmid-Wendtner MH, Burgdorf W. Ultrasound scanning in dermatology. Arch Dermatol. 2005;141:217–224
  28. Halder RM, Nootheti PK. Ethnic skin disorders overview. J Am Acad Dermatol. 2003;48:S143–S148

PII: S0022-3476(07)00963-8

doi: 10.1016/j.jpeds.2007.10.006

The Journal of Pediatrics
Volume 152, Issue 5 , Pages 622-628 , May 2008

Article Tools

* Image Usage & Resolution